{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel.","id":"OG000","title":"Standard Radiation Therapy"},{"description":"A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19.","id":"OG001","title":"Adaptive Radiation Therapy"}],"populationDescription":"The data required for this analysis was not obtained.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during treatment, then 1, 3, 6, 9, 12, 18, 24, 30, 36, 48, and 60 months after end of protocol treatment, then annually. Maximum follow-up at time of reporting was 7.3 years.","title":"Quantify Relationship Between Biomarkers and Two-year Local-regional Progression-free (LRPF) Survival (NRG)","type":"OTHER_PRE_SPECIFIED"}